The stock's rise snapped a four-day losing streak.

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...

Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...

This was the stock's second consecutive day of losses.

Who would've thought that a child's toy would've been the inspiration for the name of the greatest spectacle in professional sports? It's safe to say that not even Lamar Hunt, the man who is ...

Multiple US government agencies have ordered employees “to remove gender identifying pronouns from email signature blocks by 5:00 PM” on Friday, according to internal emails seen by CNN.

WASHINGTON ‒ Federal employees at multiple departments were instructed Friday to remove personal pronouns from their email signatures by 5 p.m. as agencies rushed to carry out President Donald ...

and email signatures. Designhill is a leading creative marketplace that offers a wide range of design services, including an AI-powered logo maker tool. The Designhill logo maker enables businesses ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...

Khaleda Rahman is Newsweek's National Correspondent based in London, UK. Her focus is reporting on abortion rights, race, education, sexual abuse and capital punishment. Khaleda joined Newsweek in ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...